Core Insights - Revvity, Inc. (RVTY) is launching a program to enhance early detection of type 1 diabetes (T1D), impacting over nine million people globally, with support from Sanofi [1][8] - The initiative marks a strategic shift from Revvity's focus on genomic and rare diseases to large-scale clinical diagnostics [2][7] Product Development - The program centers on a 4-plex T1D autoantibody assay validated on Revvity's GSP instrument, utilizing both capillary dried blood spot and venous samples for early detection [3][7] - The GSP system's high-throughput capability addresses scalability challenges in routine clinical T1D screening, with regulatory submissions to the FDA and European IVDR indicating rapid commercialization plans [4][8] Market Performance - RVTY shares have decreased by 17.8% this year, contrasting with a 0.4% decline in the industry and a 15% increase in the S&P 500 Index [5] Strategic Collaboration - The partnership with Sanofi aims to expand access to Revvity's lab-developed tests globally while advancing regulatory-cleared diagnostics, enhancing clinical credibility and adoption [9][10] Industry Outlook - The global type 1 diabetes market is projected to grow at a CAGR of 6.4%, increasing from $16.97 billion in 2025 to $26.22 billion by 2032, driven by rising disease prevalence and improved diagnostic capabilities [11][12] - Revvity's collaboration with Sanofi positions the company to capitalize on the substantial market opportunity for early detection tools, potentially redefining T1D care standards [13]

Company Overview - Revvity, Inc. (RVTY) has a market capitalization of $10 billion and is a global provider of health sciences solutions, technologies, and services, offering a wide range of products including instruments, reagents, informatics, software, imaging technologies, DNA sequencing services, and diagnostic platforms for genetic and infectious disease testing [1][2] Stock Performance - Revvity's shares have decreased by 33.1% from their 52-week high of $129.50 and have fallen 8.8% over the past three months, underperforming the Health Care Select Sector SPDR Fund (XLV), which gained 3.7% during the same period [3] - Year-to-date, RVTY stock is down 22.4%, while XLV has experienced a marginal drop. Over the past 52 weeks, Revvity shares have decreased by 29.1%, compared to XLV's 11.2% decline [4] Financial Forecast - On July 28, Revvity's shares fell 8.3% after the company revised its full-year adjusted profit forecast to $4.85 to $4.95 per share, citing weaker demand in China, where diagnostic product sales declined by double digits in Q2 2025 due to new reimbursement policies [5] - The company now expects diagnostics sales growth to be in the low single digits, down from an earlier forecast of mid-single digits [6] Analyst Sentiment - Despite the weak stock performance, analysts maintain a moderately optimistic outlook for Revvity, with a consensus rating of "Moderate Buy" from 18 analysts and a mean price target of $114.62, representing a 33.7% premium to current levels [7]

Core Insights - Revvity, Inc. (NYSE:RVTY) has launched its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, aimed at accelerating next-generation imaging innovation [2] - The company plans to enhance disease research workflows through advanced instruments and AI-driven software by integrating teams specializing in various scientific fields [3] - Revvity unveiled several advanced imaging technologies at the new center, which are expected to transform imaging modalities for cancer research and therapeutic efficacy [4] Company Developments - The launch of the In Vivo Imaging Center of Excellence consolidates Revvity's expertise in imaging technologies [2] - The company offers advanced health science solutions across multiple segments, including multi-omics, imaging, biomarkers, and informatics [5] - Revvity's new technologies include IVIS optical systems, Quantum GC3 microCT, Vega preclinical ultrasound, and VivoJect targeted delivery systems [4] Market Position - Revvity is listed among the tech stocks recommended for sale, indicating potential concerns regarding its investment attractiveness [1][5] - Despite acknowledging Revvity's potential, there are suggestions that other AI stocks may offer better upside potential with less downside risk [6]

Company Overview - The second quarter performance was good, slightly ahead of expectations for both revenue and profit [2] - The Life Science business has shown consistent stability despite pressures from pharmaceutical, biotech, and academic government customers over the past couple of years [2] Business Performance - There has been a continued low single-digit growth in consumables, which are indicative of underlying lab activity [2] - This marks the fifth consecutive quarter of sequential growth in consumables, indicating a positive trend [3] - However, the instrument segment experienced a decline in the mid- to high range [3]

Financial Data and Key Metrics Changes - The second quarter performance was slightly ahead of expectations for both top and bottom lines, with low single-digit growth in consumables indicating stability in lab activity [4][5] - Instrument sales declined mid to high single digits, consistent with previous quarters and outlook for the second half of the year [5][6] - The software business, accounting for about 9% of total revenue, has shown consistent strong growth, expected to grow in the high teens this year [5][20] Business Line Data and Key Metrics Changes - Life sciences solutions fell low single digits in the second quarter, with expectations for a slight decline for the year [7][8] - The diagnostics segment, which constitutes about half of the company, has shown good growth in the Americas and reproductive health, but faced unexpected pressures in China [6][32] - Reagents performed well, particularly in China, where the life sciences business grew mid-single digits [19] Market Data and Key Metrics Changes - Academic and government sectors saw low single-digit declines, attributed to NIH funding concerns and policy changes [8][10] - The pharma and biotech sectors remained under pressure, with performance around flat when excluding software [13][15] - The diagnostics business in China is expected to decline by 25% in the second half of the year due to new government policies affecting multiplex tests [29][30] Company Strategy and Development Direction - The company is focused on preclinical R&D and aims to stabilize its consumables business while navigating uncertainties in the market [9][10] - There is a strong emphasis on software growth, with new product launches expected to enhance market positioning [20][23] - The company is interested in both organic growth and M&A opportunities to complement its portfolio, particularly in consumables and software [48] Management's Comments on Operating Environment and Future Outlook - Management noted that the current market environment is challenging but believes in the long-term growth potential of the diagnostics and life sciences sectors [49][50] - There is optimism about the software business driving efficiencies and better data analytics, which are key areas of investment for customers [50] - The company anticipates stability in financial performance, with expectations of achieving a 28% operating margin baseline for 2026 [40][42] Other Important Information - The company has been active in share repurchase programs, buying back nearly 9% of its shares in the last 12 months [48] - The Genomics England partnership is expected to provide incremental revenue through DNA sequencing for newborns, starting in the second half of the year [35] Q&A Session Summary Question: What is the outlook for the diagnostics business in China? - Management indicated that the diagnostics business in China is expected to face a 25% decline in the second half of the year due to new government policies affecting multiplex tests [29][30] Question: How is the software business performing? - The software business is expected to grow in the high teens this year, outperforming long-term growth assumptions [20][21] Question: What are the biggest opportunities for the company in the next 12 to 18 months? - The software business and the diagnostics segment, particularly in the U.S., are seen as key opportunities for growth [50][51]

Financial Data and Key Metrics Changes - The company reported 3% organic growth in Q2, with life sciences slightly above that in the mid-single-digit range and diagnostics in the low single-digit range [4][5] - The guidance for the full year has been adjusted down to 2% to 4% organic growth, a decrease of 100 basis points primarily due to the impact of China diagnostics [44][70] - The company expects a significant sequential increase in Q4, projecting mid-single-digit growth driven by diagnostics, particularly from the OMICS contract with Genomics England [47][49] Business Line Data and Key Metrics Changes - The life sciences segment saw mid-single-digit growth, largely attributed to the Signals business, which grew over 30% [12][14] - The reagents business has shown consistent sequential growth for six straight quarters, with demand primarily driven by pharma [25][26] - The diagnostics business in China faced a 15% decline in Q2, with expectations of a mid-20% decline in the second half due to changes in reimbursement policies [7][8] Market Data and Key Metrics Changes - The company’s exposure to the China diagnostics market is about 9% of total revenue, with overall China contributing 15% to 16% of revenue [8][9] - The U.S. market for the company’s A&G segment is approximately 5% of the revenue base, with expectations of a similar market environment in the second half of the year [19][21] - The company anticipates continued growth in the life sciences sector in China, with mid-single-digit growth expected for the second half [23][24] Company Strategy and Development Direction - The company is focusing on expanding its software offerings and transitioning to a SaaS model, with a strong emphasis on customer retention and growth in annualized portfolio value [15][17] - The strategy includes increasing automation in the U.S. market to enhance competitiveness, particularly in the ImmunoDX business [37][38] - The company aims to leverage its competitive advantages in customer service and product quality to capture market share from competitors [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed cautiousness regarding the operating environment, particularly in the pharma sector, due to uncertainty in policies affecting investment planning [18][26] - The company remains optimistic about its margin expansion potential, projecting a baseline operating margin of 28% for 2026 despite current low single-digit growth expectations [55][57] - Management highlighted the importance of clarity in regulatory policies to drive growth and investment in the coming years [26][66] Other Important Information - The company has achieved a free cash flow conversion rate of 90% in the first half of the year, with expectations to maintain this trend moving forward [66][68] - Share buybacks have increased significantly, with the company planning to continue repurchasing shares at favorable prices [69][70] Q&A Session Summary Question: What is the outlook for organic growth in 2026? - Management indicated that while the market is expected to remain flat to slightly up, they anticipate growing a couple of hundred basis points above that, aiming for low single-digit growth [62][64] Question: How is the company addressing tariff impacts? - The company has operationally mitigated some tariff impacts, particularly from China, but expects to absorb some net costs moving forward [9][61] Question: What are the key competitive advantages in the reagents business? - Management believes their customer service, product quality, and market approach provide significant competitive advantages over peers [29][30]

Financial Data and Key Metrics Changes - The company reported 3% organic growth in Q2, with life sciences slightly above that in the mid-single-digit range and diagnostics in the low single-digit range [4][5] - The guidance for the full year has been adjusted down to 2% to 4% organic growth, primarily due to the impact of diagnostics in China [44][56] Business Line Data and Key Metrics Changes - Life sciences software grew over 30% in Q2, while the reagents business continued to show sequential growth [12][15] - Diagnostics in China faced a significant headwind, with a 15% decline in Q2 and a projected mid-20% decline for the second half of the year [7][9] - The pharma segment saw mid-single-digit growth, driven by the strength in the Signals business [12][13] Market Data and Key Metrics Changes - The China diagnostics business accounts for about 9% of total company revenue, with overall exposure to China being 15% to 16% [9] - The U.S. A&G market represents about 5% of the revenue base, with expectations of a similar market environment in the second half of the year [20][22] Company Strategy and Development Direction - The company is focusing on expanding its software offerings and enhancing automation in the U.S. market to improve competitiveness [36][62] - There is an emphasis on driving productivity through integration synergies from past acquisitions and supply chain activities to mitigate tariff impacts [57][58] Management's Comments on Operating Environment and Future Outlook - Management expressed cautiousness regarding the operating environment, particularly in the pharma sector, until there is clarity on policies [19][62] - The company anticipates a gradual ramp-up in diagnostics and expects to see growth in reagents and specialty areas of life sciences [25][62] Other Important Information - The company achieved a free cash flow conversion of 90% in the first half of the year, guiding for over $500 million in free cash flow for the year [64][66] - The management believes that the software business is underappreciated by investors and has significant growth potential [68] Q&A Session Summary Question: What is the outlook for organic growth? - The company is now calling for organic growth of 2% to 4%, down 100 basis points from previous guidance, primarily due to the impact of China diagnostics [44] Question: How is the company addressing tariff impacts? - The net impact of tariffs is about a $0.12 headwind, primarily affecting the diagnostics business in Europe, with operational mitigations already in place for China [10][11] Question: What is the growth outlook for the software business? - The software business is expected to grow significantly, with a net retention rate of 115% and strong annualized portfolio value growth [15][33] Question: How is the company performing in the reproductive health sector? - The reproductive health business is expected to grow mid-single digits, driven by geographic expansion and menu adoption despite falling birth rates [38][40] Question: What are the expectations for the fourth quarter? - The company expects a sequential increase in organic growth in Q4, driven by diagnostics and reproductive health, with a projected mid-single-digit growth rate [44][49]

Financial Data and Key Metrics Changes - The company reported 3% organic growth in Q2, with life sciences slightly above that in the mid-single-digit range and diagnostics in the low single-digit range [4][5] - The guidance for the full year has been adjusted down to 2% to 4% organic growth, primarily due to the impact of China diagnostics [44][56] - The net impact of tariffs is estimated to be a $0.12 headwind, equating to about a 50 basis points impact on operating margins [10][11] Business Line Data and Key Metrics Changes - The life sciences segment saw mid-single-digit growth, driven by a strong performance in the Signals business, which grew over 30% [12][15] - The diagnostics business in China faced a significant headwind, with a reported decline of about 15% in Q2 and guidance for a mid-20% decline in the second half [7][9] - The reagents business has shown sequential growth for six consecutive quarters, with demand particularly strong in pharma and China [26][27] Market Data and Key Metrics Changes - The company’s exposure to the China diagnostics market is about 9% of total revenue, with overall China contributing 15% to 16% of revenue [9] - The U.S. A&G market represents about 5% of the revenue base, with expectations of a similar market environment in the second half of the year [20][22] - The Americas market for ImmunoDX has grown from less than 5% to over 15% of revenue, with expectations for continued growth driven by FDA approvals and automation [35][36] Company Strategy and Development Direction - The company is focusing on expanding its software business, which is expected to continue growing, with a transition to SaaS and strong net retention rates [15][33] - There is an emphasis on increasing automation in the U.S. market to remain competitive, particularly in the ImmunoDX segment [36] - The company aims to leverage its competitive advantages in customer service and product quality to capture market share from competitors [29] Management's Comments on Operating Environment and Future Outlook - Management expressed cautiousness regarding the operating environment, particularly in pharma, due to unclear policies affecting investment planning [19] - The company anticipates a challenging market heading into next year, with expectations of low single-digit growth and continued pressure on instrumentation until clarity on policies is achieved [56][63] - The management remains optimistic about the long-term margin potential, projecting mid-30% operating margins once market conditions normalize [68] Other Important Information - The company achieved a free cash flow conversion rate of 90% in the first half of the year, with guidance for over $500 million in free cash flow for the year [64][66] - The company is actively engaging in share repurchases, viewing current share prices as an attractive opportunity [66] Q&A Session Summary Question: What is the outlook for organic growth? - The company is now guiding for organic growth of 2% to 4%, down from previous expectations, primarily due to the impact of China diagnostics [44] Question: How is the company addressing tariff impacts? - The net impact of tariffs is about a $0.12 headwind, with most effects felt in Europe, and operational mitigations are in place for China [10][11] Question: What is the growth outlook for the software business? - The software business is expected to grow significantly, with a net retention rate of 115% and strong annualized portfolio value growth [15][33] Question: How is the company performing in the diagnostics market? - The diagnostics business in China is facing challenges, with a projected mid-20% decline in the second half, while growth outside of China remains stable [7][48] Question: What are the expectations for the fourth quarter? - The company anticipates a sequential increase in growth rates, driven by diagnostics and reproductive health, with a projected mid-single-digit growth in Q4 [44][49]

PART I. FINANCIAL INFORMATION [Item 1. Unaudited Financial Statements](index=4&type=section&id=Item%201.%20Unaudited%20Financial%20Statements) Unaudited financial statements for Q2 and H1 2025 show revenue growth, mixed net income trends, and decreased operating cash flow to $262.5 million [Condensed Consolidated Statements of Operations](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 operations show revenue growth to $720.3 million, operating income increase, but a slight net income decrease to $53.9 million Consolidated Statements of Operations Highlights (In thousands, except per share data) | Metric | Three Months Ended June 29, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 29, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | **Total Revenue** | $720,284 | $691,685 | $1,385,046 | $1,341,605 | | **Operating Income from Continuing Operations** | $90,760 | $85,724 | $162,990 | $129,840 | | **Net Income** | $53,948 | $55,360 | $96,185 | $81,373 | | **Diluted EPS (Net Income)** | $0.46 | $0.45 | $0.81 | $0.66 | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 29, 2025, total assets were $12.36 billion, with cash decreasing to $991.8 million and total liabilities increasing Balance Sheet Summary (In thousands) | Account | June 29, 2025 | December 29, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $991,849 | $1,163,396 | | Goodwill | $6,614,989 | $6,463,619 | | Total Assets | $12,362,789 | $12,392,478 | | Long-term debt | $3,214,324 | $3,150,476 | | Total Liabilities | $4,806,621 | $4,725,604 | | Total Stockholders' Equity | $7,556,168 | $7,666,874 | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) H1 2025 operating cash flow decreased to $262.5 million, while financing cash outflow significantly increased to $466.1 million due to share repurchases Cash Flow Summary (In thousands) | Cash Flow Activity | Six Months Ended June 29, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $262,473 | $306,184 | | Net cash (used in) provided by investing activities | $(15,871) | $103,310 | | Net cash used in financing activities | $(466,139) | $(61,508) | | Effect of exchange rate changes on cash | $48,075 | $(12,931) | | **Net (decrease) increase in cash** | **$(171,462)** | **$335,055** | - Purchases of common stock amounted to **$447.5 million** in the first six months of 2025, a significant increase from **$30.3 million** in the same period of 2024[24](index=24&type=chunk)[25](index=25&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail segment realignment, a **$1.0 billion** stock repurchase program with **$414.5 million** remaining, and total debt of **$3.2 billion** - Effective at the beginning of fiscal year 2025, the company integrated its Applied Genomics business from the Diagnostics segment into the Life Sciences segment. Prior period financials have been reclassified for comparability[43](index=43&type=chunk)[44](index=44&type=chunk) - The company's Board authorized a **$1.0 billion** stock repurchase program expiring in October 2026. As of June 29, 2025, **$414.5 million** remained available for repurchases[50](index=50&type=chunk) - The company declared a quarterly cash dividend of **$0.07 per share** for the first two quarters of 2025 and announced the same for the third quarter[53](index=53&type=chunk) - Total debt as of June 29, 2025, had a net carrying amount of **$3.215 billion**, primarily consisting of various senior unsecured notes[39](index=39&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q2 2025 revenue growth to $720.3 million, gross margin decline from tariffs, and strong liquidity with $991.8 million cash [Overview](index=24&type=section&id=Overview) Q2 2025 revenue grew **4%** to **$720.3 million**, driven by Life Sciences and Diagnostics, despite a **123 basis point** gross margin decline Q2 2025 Performance vs. Q2 2024 | Metric | Change | Driver(s) | | :--- | :--- | :--- | | Total Revenue | +4% | Growth in both Life Sciences (+5%) and Diagnostics (+3%) segments | | Gross Margin | -123 bps | Increased tariffs and product mix shift, partially offset by pricing | | Operating Margin | +20 bps | Sales volume leverage and productivity gains | - Effective at the beginning of fiscal year 2025, the company moved its Applied Genomics business from the Diagnostics segment to the Life Sciences segment[84](index=84&type=chunk) [Consolidated Results of Continuing Operations](index=25&type=section&id=Consolidated%20Results%20of%20Continuing%20Operations) Q2 2025 revenue increased **4%** to **$720.3 million**, but gross margin declined **123 basis points** due to tariffs and product mix - The company estimates that recently enacted tariffs could increase its cost of revenue for the current fiscal year by approximately **$25 million**, with mitigation actions expected to limit the gross margin impact to about **$20 million**[95](index=95&type=chunk) Q2 2025 vs Q2 2024 Expense Analysis | Expense Line | Q2 2025 ($M) | Q2 2024 ($M) | Change (%) | Key Drivers | | :--- | :--- | :--- | :--- | :--- | | Cost of Revenue | $327.7 | $306.2 | +7% | Increased tariffs, unfavorable FX, product mix | | SG&A | $248.5 | $251.7 | -1% | Lower amortization and litigation costs | | R&D | $53.3 | $48.1 | +11% | Investments in new product development, unfavorable FX | - The effective tax rate is expected to be approximately **20%** for fiscal year 2025, before discrete items[103](index=103&type=chunk) [Reporting Segment Results of Continuing Operations](index=27&type=section&id=Reporting%20Segment%20Results%20of%20Continuing%20Operations) Q2 2025 Life Sciences revenue grew **5%** to **$365.9 million** and Diagnostics revenue grew **3%** to **$354.4 million**, both with operating margin declines Q2 2025 Segment Performance vs. Q2 2024 | Segment | Revenue ($M) | Revenue Growth (%) | Operating Income ($M) | Operating Margin Change (bps) | | :--- | :--- | :--- | :--- | :--- | | Life Sciences | $365.9 | 5% | $115.5 | -218 bps | | Diagnostics | $354.4 | 3% | $89.4 | -179 bps | - Life Sciences revenue growth was driven by a **$17.1 million** increase in Software revenue[106](index=106&type=chunk) - Diagnostics revenue growth was driven by increases in both Immunodiagnostics (**$5.6 million**) and Reproductive Health (**$5.7 million**)[110](index=110&type=chunk) [Liquidity and Capital Resources](index=28&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with **$991.8 million** cash and **$1.5 billion** credit, using **$447.5 million** for H1 2025 share repurchases - As of June 29, 2025, the company had **$991.8 million** in cash and cash equivalents and **$1.5 billion** of available borrowing capacity[118](index=118&type=chunk) - The company expects to use proceeds from the sale of its former business for debt retirement, share repurchases, and strategic acquisitions[117](index=117&type=chunk) - Net cash used in financing activities increased to **$466.1 million** in H1 2025 from **$61.5 million** in H1 2024, largely due to a significant increase in share repurchases (**$447.5 million** vs. **$30.3 million**)[126](index=126&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=30&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company manages market risks from foreign currency and interest rates using derivatives, with no material changes from its 2024 Form 10-K disclosures - The company's primary market risks are foreign currency exchange rates and interest rate changes[130](index=130&type=chunk) - The company uses derivative transactions to hedge against known or forecasted market exposures, but no interest rate hedge instruments were outstanding at June 29, 2025[130](index=130&type=chunk)[133](index=133&type=chunk) - The company's market risks are not materially different from those disclosed in its 2024 Form 10-K[131](index=131&type=chunk) [Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of June 29, 2025, with no material changes to internal control over financial reporting - The CEO and CFO concluded that as of June 29, 2025, the company's disclosure controls and procedures were effective at the reasonable assurance level[135](index=135&type=chunk) - No changes were identified during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[136](index=136&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=32&type=section&id=Item%201.%20Legal%20Proceedings) The company is subject to various legal proceedings, with management not expecting a material adverse effect on financial statements - The company is subject to various legal proceedings arising from its ordinary business activities[139](index=139&type=chunk) - Management believes the total cost of resolving current contingencies will not have a material adverse effect on its consolidated financial statements[139](index=139&type=chunk) [Risk Factors](index=32&type=section&id=Item%201A.%20Risk%20Factors) Key risks include market dependence, global instability, innovation, supply chain, cybersecurity, intangible asset impairment, and regulatory compliance - **Business & Economic Risks:** The business is sensitive to declines in customer markets, government funding cuts, and global economic conditions, including tariffs and trade barriers[140](index=140&type=chunk)[141](index=141&type=chunk) - **Innovation & Competition Risk:** Failure to introduce new products in a timely manner in a technologically competitive landscape could lead to loss of market share[144](index=144&type=chunk) - **Supply Chain Risk:** The company relies on limited or single-source suppliers for certain critical components, and disruptions could adversely affect operations[154](index=154&type=chunk) - **IT & Cybersecurity Risk:** A significant disruption or security breach of information technology systems could result in financial loss, reputational damage, and misappropriation of assets[158](index=158&type=chunk)[159](index=159&type=chunk) - **Financial Risk:** The company has substantial debt, which could impact future financing and flexibility. It also faces risk of intangible asset impairment, with goodwill and other intangibles totaling **$9.1 billion**[160](index=160&type=chunk)[175](index=175&type=chunk) - **Regulatory & Legal Risk:** The company is subject to extensive regulation (FDA, environmental, data privacy) and faces risks of product liability claims and non-compliance penalties[166](index=166&type=chunk)[167](index=167&type=chunk)[171](index=171&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) Q2 2025 saw the company repurchase **3,103,930 shares** at **$94.34** average, leaving **$414.5 million** available in the repurchase program Issuer Repurchases of Equity Securities for Q2 2025 | Period | Total Shares Purchased | Average Price Paid Per Share | Shares Purchased as Part of Program | Approx. Dollar Value Remaining in Program | | :--- | :--- | :--- | :--- | :--- | | Mar 31 - Apr 27, 2025 | 1,562,485 | $96.04 | 1,561,807 | $557,209,881 | | Apr 28 - May 25, 2025 | 1,091,354 | $91.71 | 1,090,425 | $457,209,962 | | May 26 - Jun 29, 2025 | 450,091 | $94.81 | 450,000 | $414,544,747 | | **Total for Quarter** | **3,103,930** | **$94.34** | **3,102,232** | **$414,544,747** | - The Board authorized a **$1.0 billion** stock repurchase program on October 24, 2024, which will expire on October 23, 2026[190](index=190&type=chunk) [Other Information](index=40&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during Q2 2025 - No directors or officers adopted or terminated Rule 10b5-1 trading plans during the three months ended June 29, 2025[188](index=188&type=chunk) [Exhibits](index=41&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO/CFO certifications and Inline XBRL data files

Group 1 - Revvity, Inc. (NYSE: RVTY) operates in the life sciences and diagnostics markets, providing instruments, reagents, and assays [1] - Approximately 80% of Revvity's total revenues come from recurring business, indicating a stable revenue model [1] - The company is strategically focused on key growth markets, particularly in cell and gene therapy [1]